The Chinese Tian Shan is one of the most actively growing orogenic ranges in Central Asia. The Late Miocene‐Quaternary landscape evolution of northern Tian Shan has been significantly driven by the interaction between tectonic deformations and climate change, further modulated by the erosion of the upstream bedrocks and deposition into the downstream basins. In this study, only the accessible Kuitun River drainage basin in northern Tian Shan was considered, and detrital zircon geochronology and heavy minerals were analyzed to investigate the signature of the driving forces for Miocene sedimentation in northern Tian Shan. This study first confirmed a previously recognized tectonic uplift at ca. 7.0 Ma and further revealed that the basin sediments were mainly derived from the present glacier‐covered ridge‐crest regions during 3.3–2.5 Ma. It is suggested Late‐Pliocene to Early Pleistocene sedimentation was likely a response to the onset of the northern hemispheric glaciation. Although complicated, this study highlights that the tectonic‐climatic interaction during the Late Cenozoic orogenesis can be discriminated in the northern Chinese Tian Shan.

In our study, more joint fluid was aspirated from patients in the supine position than from patients in the sitting position.

Objective To investigate the efficacy and safety of rituximab (RTX) maintenance therapy compared with traditional immunosuppressive agent (ISA) maintenance therapy in patients with relapsing or refractory systemic lupus erythematosus (SLE). Methods It is a prospective observational non-randomized cohort study. The study enrolled SLE patients in four centres who had received at least one course of RTX induction treatment. Patients with a clinical response to RTX were divided into two groups based on their maintenance therapy in the first 12 months: RTX group and ISA group. The relapse-free survival times were compared between the two groups. Univariate and multivariate analyses were conducted to identify predictive factors for disease relapse. Results Among the 82 patients included in the cohort, 67 (81.7%) patients had a clinical response at 6 months. RTX maintenance therapy was applied in 34 (50.7%) patients and ISA maintenance therapy was applied in the remaining 33 (49.3%) patients. After a median follow-up of 24 months, a total of 13 (19.4%) patients had experienced disease relapse, comprising 3 in the RTX group and 10 in the ISA group. Patients in the RTX group had a higher relapse-free survival rate than patients in the ISA group. Multivariate analysis identified hydroxychloroquine use, RTX maintenance therapy, and haematological system involvement as independent predictors for sustained remission. Conclusion This multicentre prospective cohort study demonstrated that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy.